BioCentury
ARTICLE | Company News

Five Prime, Bristol-Myers deal

October 19, 2015 7:00 AM UTC

Five Prime granted Bristol-Myers Squibb exclusive, worldwide rights to its colony-stimulating factor 1 receptor ( CSF1R; C-FMS; CD115) antibody program, including clinical candidate FPA008. The deal replaces a 2014 agreement to test FPA008 in combination with BMS’s melanoma drug Opdivo nivolumab.

Five Prime will receive $350 million up front. The company is eligible for up to $1.1 billion in milestones per CSF1R product for oncology indications, including $505 million for combinations with Opdivo, plus $340 million in milestones per CSF1R product for non-oncology indications. Five Prime is eligible for double-digit royalties. ...